Inclusion:- Age ≥18 years- Histologically proven adenocarcinoma of the prostate- Low-risk or intermediate-risk prostate cancer according to NCCN risk categories (low risk: T1c-T2a, Gleason score ≤6, and PSA <10 μg/L; intermediate risk: T2b-T2c or Gleason score 7 or PSA 10-20 μg/L)- Patients with pT1a/b tumor diagnosis after transurethral resection of the prostate (TURP)- Domain score of 17-25 on the International Index of Erectile Function-5 (IIEF-5) questionnaire- Karnofsky score of 70-100- Written informed consent. The gene discussed is KLK3; the disease is prostate adenocarcinoma.